Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

NCT06243354 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

257

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety
Tolerability
Efficacy

Interventions

DRUG: Test product: HYP-2090PTSA

Sponsor

Sichuan Huiyu Pharmaceutical Co., Ltd